Aurobindo’s AuroLife Warned By FDA Over Leaky Facilities
Warning Letter Notes Multiple Incidences Of Water Leakage At New Jersey Plant
After issuing Form 483 observations, the FDA has issued a warning letter to Aurobindo’s AuroLife linked to its manufacturing facility in New Jersey. The agency has warned that if the violations are not corrected promptly, it will take further action to ensure quality control.
